UroGen Pharma ( NASDAQ:URGN ) Full Year 2023 Results Key Financial Results Revenue: US$82.7m (up 28% from FY 2022). Net...
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript March 14, 2024 UroGen Pharma Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the UroGen Pharma Full […]
Key Financial Metrics Indicate Progress and Hurdles for UroGen Pharma